Skip to main content
. 2021 Mar 1;36(6):689–695. doi: 10.1177/0885066621997039

Figure 1.

Figure 1.

(A) Ln (MA) vs. ln(D-dimer) with linear regression for patients on heparin, bivalirudin, and aggregated patients. (B) Ln (MA) vs. ln(fibrinogen) with linear regression for patients on heparin, bivalirudin, and aggregated patients.